Streetbeat News

Stock Prices

WAB

Wabtec has raised its 2024 financial guidance, now expecting sales between $10.25B-$10.55B, up from the previous $10.05B-$10.35B, and adjusted EPS of $7-$7.40, increased from $6.50-$6.90. These figures surpass the consensus estimates of $10.205B in sales and $6.79 EPS. Additionally, Wabtec anticipates an operating cash flow conversion of over 90% for the full year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:36 am

HAS

Hasbro anticipates a decline in its Consumer Products Segment revenue ranging from 7% to 12% for the fiscal year 2024.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:36 am

HUM

Humana has increased its forecast for 2024 Individual Medicare Advantage membership growth by 50,000, now expecting an annual increase of 150,000 members, or 2.8%. This adjustment reflects the company's positive outlook on its ability to attract and retain members in the competitive Medicare Advantage market.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:36 am

BSX

Boston Scientific has updated its net sales growth forecast for 2024, projecting an increase of 11%-13% on a reported basis and 10%-12% on an organic basis. This is a significant improvement from the previously guided ranges of approximately 8.5%-9.5% and 8%-9%, respectively.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:36 am

T

AT&T has reaffirmed its 2024 financial outlook, projecting adjusted earnings per share (EPS) in the range of $2.15 to $2.25, which is higher than the estimated $2.07. This update underscores the company's confidence in its future financial performance.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:35 am

HUM

Humana has reaffirmed its FY24 adjusted EPS outlook at approximately $16.00, against analysts' expectations of $16.36. However, it revised its FY 2024 EPS guidance on a GAAP basis to approximately $13.93 from the previously stated $14.87.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:34 am

HAS

Hasbro (NASDAQ:HAS) reported Q1 adjusted earnings of $0.61 per share, surpassing the $0.27 estimate, marking a 125.93% beat and a 6000% increase from last year's $0.01. Q1 sales reached $757.30M, exceeding the $738.61M estimate by 2.53%, despite a 24.35% decrease from last year's $1.00B.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:34 am

BSX

Boston Scientific (NYSE:BSX) reported Q1 2024 adjusted EPS of $0.56, surpassing the $0.51 estimate, and sales of $3.856B, exceeding the $3.685B estimate. This represents a 19.15% increase in earnings and a 13.78% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:32 am

HUM

Humana (NYSE:HUM) reported Q1 2024 adjusted earnings of $7.23 per share, surpassing the consensus estimate of $6.12 by 18.14%. Adjusted sales reached $29.332 billion, exceeding estimates of $28.473 billion by 3.02% and marking a 14.35% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:32 am

WAB

Westinghouse Air Brake (WAB) reported Q1 2024 adjusted EPS of $1.89, surpassing the $1.49 estimate, and sales of $2.497B, exceeding the $2.397B estimate. This represents a 47.66% increase in EPS and a 13.81% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 24, 2024 | 10:31 am